U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H20O3
Molecular Weight 224.2961
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of METHYL JASMONATE

SMILES

CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O

InChI

InChIKey=GEWDNTWNSAZUDX-WQMVXFAESA-N
InChI=1S/C13H20O3/c1-3-4-5-6-11-10(7-8-12(11)14)9-13(15)16-2/h4-5,10-11H,3,6-9H2,1-2H3/b5-4-/t10-,11-/m1/s1

HIDE SMILES / InChI

Description

Methyl jasmonate (MJ) is a natural cyclopentanone lipid belonging to the jasmonates (JAs) family of plant oxylipin stress hormones (oxygenated fatty acids). Methyl jasmonate is found universally in the plant kingdom and functions to regulate plant growth and development, as well as in stress responses through signal transduction pathways. Methyl jasmonate has recently been found to have anti-cancer activity. MJ (1) arrests cell cycle, inhibiting cell growth and proliferation, (2) causes cell death through the intrinsic/extrinsic proapoptotic, p53-independent apoptotic, and nonapoptotic (necrosis) pathways, (3) detaches hexokinase from the voltage-dependent anion channel, dissociating glycolytic and mitochondrial functions, decreasing the mitochondrial membrane potential, favoring cytochrome c release and ATP depletion, activating pro-apoptotic, and inactivating antiapoptotic proteins, (4) induces reactive oxygen species mediated responses, (5) stimulates MAPK-stress signaling and redifferentiation in leukemia cells, (6) inhibits overexpressed proinflammatory enzymes in cancer cells such as aldo-keto reductase 1 and 5-lipoxygenase, and (7) inhibits cell migration and shows antiangiogenic and antimetastatic activities. Finally, MJ may act as a chemosensitizer to some chemotherapics helping to overcome drug resistant. The complete lack of toxicity to normal cells and the rapidity by which MJ causes damage to cancer cells turn MJ into a promising anticancer agent that can be used alone or in combination with other agents. Methyl jasmonate detached hexokinase 2 from a voltage-dependent anion channel causing a reduction in mitochondrial transmembrane potential that led to the release of cytochrome C and apoptosis inducing factor resulting in intrinsic apoptosis. Blocked adenosine triphosphate synthesis caused by mitochondrial injury hampered oxidative phosphorylation and led to cell necrosis. Methyl jasmonate may be an adjuvant therapy for liver tumors due to its mechanism in cancer cells compared to that in normal cells: The major function is to inhibit glycolysis instead of changing aerobic metabolism.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Humans (preneoplastic and malignant skin lesions treatment): Methyl jasmonate was applied topically on cancerous and pre-cancerous skin lesions from eight patients. Mice (hepatocellular carcinoma treatment): Nude mice received a daily dose of saline, Methyl jasmonate (50 mg/kg), sorafenib (10 mg/kg) and sorafenib (10 mg/kg) combined with Methyl jasmonate (50 mg/kg) by gavage after the formation of neoplasia (diameter 0.5 cm)
Route of Administration: Other
In Vitro Use Guide
W620 cells were treated with 0, 0.5, 0.75, 1.5 and 2.0 mM methyl jasmonate for 12, 24 and 48 h. Methyl jasmonate was shown to be able to inhibit cell growth and induce apoptosis of SW620 cells in a concentration and time‑dependent manner, whilst promoting an increase in caspase‑3 protein expression.